NeoGenomics (NEO) COO details RSU vesting and tax share sale in Form 4
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
NeoGenomics (NEO) President & Chief Operating Officer Warren Stone reported equity activity on January 13, 2026. He acquired 59,382 shares of common stock through the vesting of restricted stock units at an effective price of $0 per share, then disposed of 15,127 shares in a transaction tied to tax withholding obligations. Following these transactions, he directly beneficially owned 143,759 shares of NeoGenomics common stock.
The filing also lists substantial outstanding equity awards, including stock options, restricted stock units, and performance stock units covering multiple future vesting and expiration dates, reflecting a significant portion of his compensation in equity incentives.
Positive
- None.
Negative
- None.
Insider Trade Summary
17 transactions reported
Mixed
17 txns
Insider
Stone Warren
Role
Pres & Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Common Stock | 59,382 | $0.00 | -- |
| Tax Withholding | Common Stock | 15,127 | $0.00 | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Performance Stock Unit | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Performance Stock Unit | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Performance Stock Unit | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
Holdings After Transaction:
Common Stock — 158,886 shares (Direct);
Stock Option (Right to Buy) — 166,113 shares (Direct);
Performance Stock Unit — 21,204 shares (Direct);
Restricted Stock Unit — 9,613 shares (Direct)
Footnotes (1)
- Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. On December 1, 2022, Mr. Stone was granted 166,113 stock options. The options vest ratably over the first four anniversary dates of the grant date. On May 11, 2023, Mr. Stone was granted 53,969 stock options. The options vest ratably over the first three anniversary dates of the grant date. On May 11, 2023, Mr. Stone was granted 21,204 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is31,806. The number of performance stock units that may vest is based on the achievement of certain growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company. Once vested, the shares of common stock are not subject to expiration. On May 11, 2023, Mr. Stone was granted 28,838 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. On February 23, 2024, Mr. Stone was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date. On February 23, 2024, Mr. Stone was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. On February 23, 2024, Mr. Stone was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. On May 2, 2024, Mr. Stone was granted 29,976 stock options. The options vest ratably over the first three anniversary dates of the grant date. On May 2, 2024, Mr. Stone was granted 17,905 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. On May 2, 2024, Mr. Stone was granted 17,908 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is26,862. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110% On February 21, 2025, Mr. Stone was granted 143,266 stock options. At the time of the grant, the options vested ratably over the first three anniversary dates of the grant date. In connection with Mr. Stone's promotion to President &Chief Operating Officer on April 1, 2025, the vesting schedule of these options was modified so that they now vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date. On February 21, 2025, Mr. Stone was granted 84,317 restricted stock units. At the time of the grant, the restricted stock units vested ratably over the first three anniversary dates of the grant date. In connection with Mr. Stone'spromotion to President & Chief Operating Officer on April 1, 2025, the vesting schedule of these restricted stock units was modified so that they now vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grantdate. This stock option was granted as a premnium-price stock option. To calculate the premium exercise price we used the closing price on April 1, 2025 and multiplied by 110%. On April 1, 2025, Mr. Stone was granted 94,518 stock options. The options vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date. On April 1, 2025, Mr. Stone was granted 52,687 restricted stock units. The restricted stock units vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date.
FAQ
What did NeoGenomics (NEO) disclose in this Form 4 for Warren Stone?
The filing shows that President & Chief Operating Officer Warren Stone had restricted stock units vest into 59,382 shares of NeoGenomics common stock on January 13, 2026, with a portion withheld to cover taxes.
What do the transaction codes M and F mean in Warren Stone’s NeoGenomics Form 4?
In this filing, code M is used for the acquisition of 59,382 shares tied to the vesting of restricted stock units, and code F is used for the 15,127-share disposition related to tax withholding on that vesting.
What types of equity awards does Warren Stone hold in NeoGenomics?
The Form 4 lists multiple stock options, restricted stock units, and performance stock units, including options for 166,113, 53,969, 42,344, 29,976, 143,266, and 94,518 shares, and various RSU and PSU awards that vest over time based on service and performance conditions.
Are Warren Stone’s NeoGenomics equity awards subject to performance conditions?
Yes. The filing describes performance stock units where vesting depends on achieving share price growth goals based on the weighted average stock price and revenue growth goals tied to cumulative fiscal year revenue, in each case subject to continued service.
Did this NeoGenomics Form 4 report any change to option or RSU vesting schedules?
Yes. The footnotes state that grants made on February 21, 2025 had their vesting schedules modified in connection with Mr. Stone’s promotion to President & Chief Operating Officer on April 1, 2025, so that they now vest at 12-, 18-, and 24-month anniversaries of the grant date.